预约演示
更新于：2025-05-08
Radotinib Dihydrochloride
拉多替尼二盐酸盐
更新于：2025-05-08
概要
基本信息
药物类型 小分子化药 |
别名 Radotinib、Radotinib hydrochloride、Supect + [4] |
作用方式 抑制剂、拮抗剂 |
作用机制 Bcr-Abl抑制剂(bcr-abl酪氨酸激酶抑制剂)、PDGFR拮抗剂(血小板衍生生长因子受体拮抗剂) |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 韩国 (2012-01-05), |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H23Cl2F3N8O |
InChIKeyGEWCZTBAWRSKBX-UHFFFAOYSA-N |
CAS号926037-85-6 |
关联
11
项与 拉多替尼二盐酸盐 相关的临床试验NCT06665412
A Single-arm, Open-label, Multicenter, Investigator-led Observational Study to Evaluate the Efficacy and Safety of Dose Reduction of Radotinib as a First-line Treatment in Patients With Newly Diagnosed Chronic Phase Ph+ Chronic Myeloid Leukemia.
NCT06461078
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib in Healthy Adults
NCT04691661
A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease
100 项与 拉多替尼二盐酸盐 相关的临床结果
登录后查看更多信息
100 项与 拉多替尼二盐酸盐 相关的转化医学
登录后查看更多信息
100 项与 拉多替尼二盐酸盐 相关的专利（医药）
登录后查看更多信息
85
项与 拉多替尼二盐酸盐 相关的文献（医药）2025-01-01BIOORGANIC CHEMISTRY
Chemotherapeutic potential of radotinib against blood and solid tumors: A beacon of hope in drug repurposing
Review
作者: Manoharan, Suryaa ; Perumal, Ekambaram
Tyrosine kinase inhibitors (TKIs) represent a pivotal class of targeted therapies in oncology, with multiple generations developed to address diverse molecular targets. Imatinib is the first TKI developed to target the BCR-ABL1 chimeric protein, which is the key driver oncogene implicated in Philadelphia chromosome-positive chronic myeloid leukemia (CML). Several second-generation tyrosine kinase inhibitors (2GTKIs), such as nilotinib, dasatinib, bosutinib, and radotinib (RTB), followed the groundbreaking introduction of imatinib. RTB occupies the unique position of being the least explored member of this class. While nilotinib, dasatinib, and bosutinib have garnered significant attention and extensive research focus, RTB remains relatively uncharted in comparison to its counterparts. Fundamental drug characteristics, such as the pharmacokinetic and pharmacodynamic properties of RTB, remain unavailable in existing sources. Compared to other 2GTKIs, RTB has been less utilized in combinatorial drug studies, and no investigations have been reported on its effects on solid tumors to date. However, the effects of RTB have been studied in acute myeloid leukemia (AML), multiple myeloma (MM), Parkinson's disease, and idiopathic pulmonary fibrosis (IPF). Although RTB has been investigated in some conditions, these studies are still in their preliminary stages and are comparatively lesser than studies on other 2GTKIs. This review is the first attempt that extensively presents a compilation of data on RTB and describes its therapeutic potential against blood and solid tumors. Further investigations on RTB could expand its chemotherapeutic usage in various solid tumors and enhance the possibility of drug repurposing in cancer therapy.
2024-12-01ARCHIV DER PHARMAZIE
Targeting STAT3, FOXO3a, and Pim‐1 kinase by FDA‐approved tyrosine kinase inhibitor–Radotinib: An in silico and in vitro approach
Article
作者: Manoharan, Suryaa ; Santhakumar, Aksayakeerthana ; Perumal, Ekambaram
Abstract:
Cancer, a multifactorial pathological condition, is primarily caused due to mutations in multiple genes. Hepatocellular carcinoma (HCC) is a form of primary liver cancer that is often diagnosed at the advanced stage. Current treatment strategies for advanced HCC involve systemic therapies which are often hindered due to the emergence of resistance and toxicity. Therefore, a multitarget approach might prove more effective in HCC treatment. The present study focuses on targeting signal transducer and activator of transcription 3 (STAT3), forkhead box class O3a (FOXO3a), and proviral integration site for Moloney murine leukemia virus‐1 (Pim‐1) kinase, using a Food and Drug Administration (FDA)‐approved anticancer drug library. Two compounds, namely, radotinib and capmatinib, were identified as top compounds using molecular docking. Among the two compounds, radotinib exhibited significant binding values towards the targeted proteins and their heterodimers. Furthermore, in vitro experiments involving 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide (MTT), live/dead, 4′,6‐diamidino‐2‐phenylindole, and clonogenic assays were performed to evaluate the effect of radotinib in human hepatoblastoma cell line/hepatocellular carcinoma cells. The gene expression data indicated reduced expression of FOXO3a and Pim‐1, but no basal‐level alteration of STAT3. The Western blot analysis assay showed that the phosphorylation level of STAT3 was significantly decreased upon radotinib treatment. Taken together, our findings suggest that radotinib, which is currently used in the treatment of chronic myeloid leukemia (CML), could be considered as a potential candidate for repurposing in the treatment of HCC.
2024-11-01INDIAN JOURNAL OF DERMATOLOGY
Radotinib-induced Eruptive Melanocytic Naevi in a Patient with Chronic Myeloid Leukaemia
Article
作者: Han, Byeol ; Choi, Jae Eun ; Lee, June H. ; Lee, Jung Min ; Han, Tae Young
4
项与 拉多替尼二盐酸盐 相关的新闻（医药）2025-04-07
·微信
优先审批临床3期上市批准申请上市
2025-02-12
·信狐药迅
2025-01-27
·医药观澜
siRNA临床3期突破性疗法临床结果上市批准
100 项与 拉多替尼二盐酸盐 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 费城染色体阳性慢性粒细胞白血病 | 韩国 | 2012-01-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性慢性粒细胞白血病 | 临床3期 | 美国 | 2018-06-25 | |
| 难治性慢性粒细胞白血病 | 临床3期 | 俄罗斯 | 2018-06-25 | |
| 难治性慢性粒细胞白血病 | 临床3期 | 土耳其 | 2018-06-25 | |
| 难治性慢性粒细胞白血病 | 临床3期 | 乌克兰 | 2018-06-25 | |
| 慢性期慢性髓性白血病 | 临床3期 | 印尼 | 2011-08-01 | |
| 慢性期慢性髓性白血病 | 临床3期 | 菲律宾 | 2011-08-01 | |
| 慢性期慢性髓性白血病 | 临床3期 | 韩国 | 2011-08-01 | |
| 慢性期慢性髓性白血病 | 临床3期 | 泰国 | 2011-08-01 | |
| 帕金森病 | 临床2期 | 法国 | - | 2021-09-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 241 | 襯廠憲襯艱鏇艱製鏇齋(艱觸鏇獵簾壓糧觸壓鹹) = 選鏇範齋鏇鹹顧網餘窪 觸糧積壓餘繭鹽積網繭 (繭衊選築艱憲範襯繭願 ) 更多 | 优效 | 2018-11-29 | |||
- | |||||||
临床3期 | 242 | 鑰繭餘艱鑰構簾製鑰餘(鏇壓築範選獵壓網膚齋) = 膚製鏇鹽膚齋衊選顧醖 選顧築遞鑰糧鑰觸觸構 (鬱鬱鹽獵膚顧築膚遞觸 ) 更多 | 积极 | 2017-12-01 | |||
鑰繭餘艱鑰構簾製鑰餘(鏇壓築範選獵壓網膚齋) = 壓糧遞蓋獵壓製窪糧選 選顧築遞鑰糧鑰觸觸構 (鬱鬱鹽獵膚顧築膚遞觸 ) 更多 | |||||||
临床2期 | 77 | 獵夢積鏇簾構蓋膚選鏇(鹽積艱醖蓋襯鬱選鏇顧) = Main reasons of discontinuation were abnormal laboratory test (n=18) 鏇獵觸簾簾膚餘鹽選膚 (網選簾壓壓糧願襯淵築 ) 更多 | 积极 | 2017-05-18 | |||
N/A | 241 | 襯鬱膚糧夢選窪蓋繭窪(艱糧選鹹衊繭選糧鏇廠) = 築鑰獵淵遞襯觸齋構壓 淵觸鏇壓齋鹽繭繭衊獵 (鑰壓窪遞網齋獵鑰艱範 ) 更多 | 积极 | 2017-05-18 | |||
襯鬱膚糧夢選窪蓋繭窪(艱糧選鹹衊繭選糧鏇廠) = 選艱鏇繭繭壓簾鬱構顧 淵觸鏇壓齋鹽繭繭衊獵 (鑰壓窪遞網齋獵鑰艱範 ) 更多 | |||||||
临床2期 | 77 | 廠衊繭製構齋淵獵鹹衊(膚範齋繭獵獵廠蓋繭膚) = 製製願願範鬱願鹽願獵 憲衊鬱願鹽製繭鑰構鑰 (廠壓網積襯艱廠願壓願 ) 更多 | 积极 | 2014-07-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用